AstraZeneca

Versant Ventures launches Pep2Tango Therapeutics, aiming to combine four obesity treatment methods into one drug. The startup, funded in the 'double-digit' millions, targets GLP-1, GIP, amylin, and calcitonin receptors for potential higher efficacy and muscle preservation. Pep2Tango's CEO, Cristina Rondinone, emphasizes the need for multi-target approaches in obesity treatment.

Molecular diagnostics market valued at $17.3 billion in 2024, expected to grow to $32.7 billion by 2029. Driven by disease prevalence, R&D funding, tech advancements, and early diagnosis awareness. Notable collaborations include Lunit-AstraZeneca for AI-driven NSCLC mutation prediction and Owkin-Proscia for colorectal cancer MSI testing. Illumina expands TruSight Oncology portfolio with TSO 500 v2 for comprehensive tumor profiling.

Scientists developed a blood test to predict prostate cancer patients' response duration to olaparib, linking DNA changes to survival. They found cancers missing BRCA2 gene regained it, developing resistance. This research aims to personalize treatment and develop new drugs to prevent resistance, improving patient outcomes.

A conference on global health and clinical trials addresses bioethics, regulations, patient recruitment, site selection, real-world data, data integration, outsourcing, vendor management, quality in trial conduct, risk-based monitoring, clinical auditing, and financial planning. It features innovative sessions on new technologies and collaborations, and networking opportunities with decision makers.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, real-world data, and risk-based monitoring, among others. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study opportunities.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, data integration, outsourcing, and risk-based monitoring. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study presentations.

The 'Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides comprehensive insights into 50+ companies and 55+ pipeline drugs for RSV, including clinical and nonclinical stage products, therapeutic assessments by product type, stage, route of administration, and molecule type, and details on collaborations, licensing, mergers, and acquisitions.

The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.

Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.